Medpace Hires Industry Expert to Direct New Bioanalytical Laboratories

CINCINNATI, July 29 /PRNewswire/ -- Medpace, a leading global full-service
contract research organization, announced it has hired Yong-Xi Li as Executive
Director of the new Medpace Bioanalytical Laboratories.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080729/CLTU002LOGO )
Dr. Li joins Medpace with a strong background in bioanalytical technology,
method development, validation, and sample analysis in support of
pharmaceutical development and both preclinical and clinical studies. At
Medpace, Dr. Li will direct operations and activities of the new, advanced
Mass Spectrometry Medpace Bioanalytical Laboratories, including bioanalytical
aspects for small and large drug molecules according to GLP and GMP
compliances and ICH guidelines. This new laboratory is projected to open in
fall of 2008 and will complement services provided by other Medpace research
facilities, such as Medpace Clinical Pharmacology and Medpace Reference
Laboratories.
Dr. Li comes to Medpace from Eurofins Scientific, NJ, where he served as
Senior Director, managing their laboratory process and facilitating
bioanalytical technology and methods. Prior to his work at Eurofins
Scientific, Dr. Li was the Vice President of Ricerca LLC and then the Vice
President of XenoBiotics Laboratories, Inc., where he led and expanded the
bioanalytical laboratories and activities.
Dr. Li arrived in the US and worked as a senior research scientist under
Dr. K.J. Klubende and Dr. B.H. Davis to establish his first bioanalytical
laboratory. He went on to do postdoctoral studies in Chemistry at Cornell
University, Baker Laboratory, in Ithaca, New York, under Professor Emeritus
S.H. Bauer. Dr. Li has authored numerous scientific and clinical publications
in the fields of proteomics and quantitation analysis.
"We are excited to have an experienced chemist such as Yong-Xi Li on
staff," said August Troendle, MD, Medpace Chief Executive Officer. "Yong-Xi's
bioanalytical expertise is a good fit for our company as we continue to expand
our laboratory capabilities."
ABOUT MEDPACE
Medpace is a leading global full-service contract research organization
led by top therapeutic and regulatory experts who are driven to further the
advancement of pharmaceutical agents for use in cardiology, metabolism, and
oncology. Medpace has assembled the industry's most experienced and
therapeutically focused team to execute at every level of the company's
operations, providing complete and seamless drug development services.
Through specialized regulatory expertise and therapeutically focused
clinical operations, Medpace creates strategic partnerships with
pharmaceutical and biotechnology companies to provide the most efficient and
cost-effective path to drug development -- from program planning and execution
to product approval.
With more than 700 employees and clinical trial experience in over 40
countries, Medpace has the global reach and capability to conduct studies and
navigate regulatory requirements worldwide within the core therapeutic areas
of cardiology, metabolism, and oncology.
Medpace provides centralized image management and reading from Imagepace,
centralized laboratory and therapeutically specialized testing from Medpace
Reference Laboratories, and Phase I / IIa research services from Medpace
Clinical Pharmacology.
Visit the Medpace website at http://www.medpace.com

Contact: John Wynne, 513-579-9911 x2407
j.wynne@medpace.com

SOURCE Medpace

John Wynne of Medpace, +1-513-579-9911, ext. 2407, j.wynne@medpace.com